Clinical-stage biotechnology company Lipella Pharmaceuticals Inc (Nasdaq:LIPO) on Tuesday announced the receipt of a US patent for its proprietary liposomal drug delivery platform.
The new patent covers key innovations in the company's technology for delivering therapeutic agents via liposome-based vehicles.
This breakthrough technology enables precise, targeted delivery, improving the safety and efficacy of treatments across various therapeutic areas, including oncology, cancer survivorship and immunotherapy. The patent extends market exclusivity for Lipella's lead clinical assets, LP-10 and LP-310, which are currently in Phase 2 trials.
LP-10 is a liposomal formulation of tacrolimus designed to treat haemorrhagic cystitis, while LP-310 is an oral rinse formulation for treating oral lichen planus. Both assets have shown promising results in clinical trials and offer potential solutions for these unmet medical needs.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial